How drug companies will profit from making Covid-19 vaccines

The world has at least two, and possibly three, Covid-19 vaccines ready to be distributed before the end of the year. In several months, millions of people will likely have received at least the first dose of a vaccine made by Pfizer, Moderna, or AstraZeneca.

While these pharmaceutical companies are filling a desperate public need, they are also corporations with shareholders expecting a return. Manufacturing coronavirus vaccines is a potentially lucrative business, but how much will these companies earn? And what will the market for Covid-19 vaccines look like in the long term?

Asking price

Read the rest of this story on qz.com. Become a member to get unlimited access to Quartz’s journalism.